SILEXION THERAPEUTICS CORP
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-11.9M | $-16.5M | $-5.1M |
| Depreciation & Amortization | — | — | — |
| Depreciation | $14.0K | $25.0K | $45.0K |
| Amortization | — | — | — |
| Stock-Based Compensation | $134.0K | $5.9M | $130.0K |
| Net Cash from Operating Activities | $-10.8M | $-8.4M | $-4.5M |
| Investing Activities | |||
| Capital Expenditures | $9.0K | $22.0K | $12.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-14.0K | $-22.0K | $573.0K |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $15.6M | $5.1M | $522.0K |
| Net Change in Cash | — | — | — |
| Free Cash Flow | $-10.8M | $-8.4M | $-4.5M |